• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

戈利木单抗治疗强直性脊柱炎患者:系统评价和荟萃分析。

Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis.

机构信息

Department of Spinal Surgery, General Hospital of Ningxia Medical University, Ningxia Medical University, 804 Shengli Street, Xingqing District, Yinchuan, 750004, Ningxia, People's Republic of China.

First Affiliated Hospital of Nanchang University, No.17 Yong Wai Zheng Street Donghu District, Nanchang, 330006, Jiangxi, People's Republic of China.

出版信息

Eur Spine J. 2020 Aug;29(8):1813-1822. doi: 10.1007/s00586-020-06466-9. Epub 2020 May 23.

DOI:10.1007/s00586-020-06466-9
PMID:32447529
Abstract

PURPOSE

The goal of this study was to review relevant randomized controlled trials in order to determine the clinical efficacy of golimumab in the treatment of ankylosing spondylitis (AS).

METHODS

Using appropriate keywords, we identified relevant studies using PubMed, Cochrane and Embase. Key pertinent sources in the literature were also reviewed, and all articles published through November 2019 were considered for inclusion. For each study, we assessed odds ratios, mean difference and 95% confidence interval to assess and synthesize outcomes.

RESULTS

We included nine studies with 6363 patients. Compared with placebo, golimumab would significant decreased the value of BASFI, BASMI, BASDAI, total back pain, JSEQ; increased the value of SF-36 PCS and SF-36 MCS; increased the incidence of BASDAI50, ASAS20, ASAS40 and ASAS partial remission. Compared with golimumab 50 mg, golimumab 100 mg would significantly decreased the value of BASFI and total back pain; increased the value of SF-36 PCS and SF-36 MCS; but also increased the incidence of SAE.

CONCLUSIONS

Golimumab had a definite effect in the treatment of AS. The higher dose would obtain better efficacy but lead to the incidence of SAE.

摘要

目的

本研究旨在回顾相关的随机对照试验,以确定戈利木单抗治疗强直性脊柱炎(AS)的临床疗效。

方法

使用适当的关键词,我们通过 PubMed、Cochrane 和 Embase 确定了相关研究。还回顾了文献中的关键来源,并考虑了截至 2019 年 11 月发表的所有文章。对于每项研究,我们评估了比值比、均数差和 95%置信区间,以评估和综合结果。

结果

我们纳入了 9 项研究,共 6363 名患者。与安慰剂相比,戈利木单抗可显著降低 BASFI、BASMI、BASDAI、总背痛、JSEQ 的评分;增加 SF-36 PCS 和 SF-36 MCS 的评分;增加 BASDAI50、ASAS20、ASAS40 和 ASAS 部分缓解的发生率。与戈利木单抗 50mg 相比,戈利木单抗 100mg 可显著降低 BASFI 和总背痛评分;增加 SF-36 PCS 和 SF-36 MCS 的评分;但也增加了 SAE 的发生率。

结论

戈利木单抗治疗 AS 具有明确的疗效。高剂量可获得更好的疗效,但会导致 SAE 的发生率增加。

相似文献

1
Patients with ankylosing spondylitis treatment by golimumab: a systematic review and meta-analysis.戈利木单抗治疗强直性脊柱炎患者:系统评价和荟萃分析。
Eur Spine J. 2020 Aug;29(8):1813-1822. doi: 10.1007/s00586-020-06466-9. Epub 2020 May 23.
2
Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study.在3期GO-ALIVE研究中,静脉注射戈利木单抗对活动性强直性脊柱炎成人患者疲劳的影响及其与临床反应的关系。
Rheumatol Ther. 2023 Aug;10(4):983-999. doi: 10.1007/s40744-023-00556-y. Epub 2023 Jun 15.
3
TNF-alpha inhibitors for ankylosing spondylitis.用于强直性脊柱炎的肿瘤坏死因子-α抑制剂
Cochrane Database Syst Rev. 2015 Apr 18;2015(4):CD005468. doi: 10.1002/14651858.CD005468.pub2.
4
Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.静脉注射戈利木单抗治疗强直性脊柱炎成人患者的安全性和疗效:GO-ALIVE 研究 1 年结果。
J Rheumatol. 2019 Oct;46(10):1277-1283. doi: 10.3899/jrheum.180718. Epub 2019 Mar 1.
5
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.阿达木单抗、依那西普和英夫利昔单抗治疗强直性脊柱炎:系统评价与经济学评估
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
6
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.戈利木单抗每 4 周皮下注射治疗强直性脊柱炎:GO-RAISE 研究的 104 周结果。
Ann Rheum Dis. 2012 May;71(5):661-7. doi: 10.1136/ard.2011.154799. Epub 2011 Oct 19.
7
Sulfasalazine for ankylosing spondylitis.柳氮磺胺吡啶用于治疗强直性脊柱炎。
Cochrane Database Syst Rev. 2014 Nov 27;2014(11):CD004800. doi: 10.1002/14651858.CD004800.pub3.
8
Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial.静脉注射戈利木单抗对强直性脊柱炎患者健康相关生活质量的影响:GO-ALIVE 试验 28 周结果。
Value Health. 2020 Oct;23(10):1281-1285. doi: 10.1016/j.jval.2020.04.1837. Epub 2020 Sep 8.
9
Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.戈利木单抗治疗中国活动性强直性脊柱炎患者的安全性和疗效:一项多中心、随机、双盲、安慰剂对照 III 期临床试验的 1 年结果。
Rheumatology (Oxford). 2014 Sep;53(9):1654-63. doi: 10.1093/rheumatology/keu132. Epub 2014 Apr 11.
10
Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials.采用 GO-ALIVE 和 ASSERT 试验数据,比较静脉注射戈利木单抗和英夫利昔单抗治疗强直性脊柱炎的倾向评分匹配/重加权分析。
Clin Rheumatol. 2020 Oct;39(10):2907-2917. doi: 10.1007/s10067-020-05051-1. Epub 2020 May 4.

引用本文的文献

1
Role of HLA class I and II alleles in susceptibility to ankylosing spondylitis in Chinese Han.中国汉族人群中 HLA Ⅰ类和Ⅱ类等位基因与强直性脊柱炎易感性的关系
J Clin Lab Anal. 2023 Sep;37(17-18):e24964. doi: 10.1002/jcla.24964. Epub 2023 Sep 25.
2
Golimumab Ameliorates Pancreatic Inflammatory Response in the Cerulein-Induced Acute Pancreatitis in Rats.戈利木单抗改善了雨蛙肽诱导的大鼠急性胰腺炎的胰腺炎症反应。
Turk J Gastroenterol. 2022 Nov;33(11):918-924. doi: 10.5152/tjg.2022.21456.
3
Effects of Different Drug Therapies and COVID-19 mRNA Vaccination on Semen Quality in a Man with Ankylosing Spondylitis: A Case Report.

本文引用的文献

1
The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?肿瘤坏死因子抑制剂在强直性脊柱炎中的安全性:肿瘤坏死因子抑制剂比我们想象的更安全吗?
J Clin Pharmacol. 2019 Apr;59(4):445-462. doi: 10.1002/jcph.1348. Epub 2018 Nov 26.
2
Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis.强直性脊柱炎给患者和医疗保健系统带来沉重负担:来自德国索赔数据库分析的结果。
Rheumatol Int. 2018 Nov;38(11):2121-2131. doi: 10.1007/s00296-018-4124-z. Epub 2018 Aug 9.
3
Proposal of a New Treatment-Oriented Classification System for Spinal Deformity in Ankylosing Spondylitis.
不同药物治疗方案和 COVID-19 mRNA 疫苗接种对强直性脊柱炎男性精液质量的影响:病例报告。
Medicina (Kaunas). 2022 Jan 24;58(2):173. doi: 10.3390/medicina58020173.
强直性脊柱炎脊柱畸形新的面向治疗的分类系统提案。
Spine Deform. 2018 Jul-Aug;6(4):366-372. doi: 10.1016/j.jspd.2017.06.001.
4
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.戈利木单抗静脉注射治疗强直性脊柱炎成人患者的安全性和疗效:GO-ALIVE 研究 28 周的结果。
J Rheumatol. 2018 Mar;45(3):341-348. doi: 10.3899/jrheum.170487. Epub 2017 Dec 15.
5
[The safety and efficacy of golimumab in treatment of 25 patients with active ankylosing spondylitis].戈利木单抗治疗25例活动性强直性脊柱炎患者的安全性和有效性
Zhonghua Nei Ke Za Zhi. 2017 Dec 1;56(12):935-939. doi: 10.3760/cma.j.issn.0578-1426.2017.12.009.
6
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.在强直性脊柱炎中每4周皮下注射戈利木单抗:GO-RAISE研究的5年结果
Ann Rheum Dis. 2015 Apr;74(4):757-61. doi: 10.1136/annrheumdis-2014-205862. Epub 2014 Nov 11.
7
The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial.戈利木单抗治疗对强直性脊柱炎患者疾病活动度及健康相关生活质量的影响:GO-RAISE试验的2年结果
J Rheumatol. 2014 Jun;41(6):1095-103. doi: 10.3899/jrheum.131003. Epub 2014 Apr 15.
8
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.戈利木单抗3年安全性更新:对类风湿关节炎、银屑病关节炎或强直性脊柱炎患者进行的随机、双盲、安慰剂对照试验长期扩展研究的汇总数据分析
Ann Rheum Dis. 2015 Mar;74(3):538-46. doi: 10.1136/annrheumdis-2013-204195. Epub 2013 Dec 16.
9
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study.戈利木单抗每 4 周皮下注射治疗强直性脊柱炎:GO-RAISE 研究的 104 周结果。
Ann Rheum Dis. 2012 May;71(5):661-7. doi: 10.1136/ard.2011.154799. Epub 2011 Oct 19.
10
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.戈利木单抗治疗强直性脊柱炎患者的疗效与安全性:一项随机、双盲、安慰剂对照的III期试验结果
Arthritis Rheum. 2008 Nov;58(11):3402-12. doi: 10.1002/art.23969.